Global Messenger RNA (mRNA) Vaccines & Therapeutics Market Share Is Expected To Grow At A CAGR Of 14.65% By 2030

17-Jan-2023 | Facts and Factors

According to Facts and Factors, the global messenger RNA (mRNA) vaccines & therapeutics market size was worth around USD 0.71 billion in 2021 and is predicted to grow to around USD 26.35 billion by 2030 with a compound annual growth rate (CAGR) of roughly 14.65% between 2022 and 2030.

Cells found in living organisms contain deoxyribonucleic acid (DNA) which in turn is full of information required for the cell to live and function as intended. Most of these activities require the help of proteins and to create them, the information contained in the DNA must pass to the cell’s machinery that makes the protein.

Browse the full “Messenger RNA (mRNA) Vaccines & Therapeutics Market Size, Share, Growth Analysis Report By Application (Infectious Diseases, Cancer, and Others), By End-User (Clinics, Hospitals, Diagnostic Centers, and Others), By Type (Infectious Disease Treatment mRNA Vaccine, Infection Prevention mRNA Vaccine, Standardization of Cancer Treatment mRNA Vaccine, and Individualized Cancer Treatment mRNA Vaccine), By Route Of Administration (Subcutaneous and IV Infusion), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030" report at https://www.fnfresearch.com/mrna-vaccines-and-therapeutics-market

Messenger RNA (mRNA) is responsible for carrying out these tasks since it collects information from DNA and takes it to the cell’s protein-producing machinery. The information tells the machinery what kind of protein has to be produced. Vaccines and therapeutics based on mRNA make use of the essential function of mRNA since it prompts the body or the cells to create a certain type of protein which then fights any unwanted invasion of the body’s immunity or organs.

The global messenger RNA (mRNA) vaccines & therapeutics market is projected to grow owing to the promising results of the vaccines on various deadly diseases like cancer, human immunodeficiency virus infection (HIV), and other infectious diseases like influenza, which are more common but serious if not treated at the right time.

As per the World Health Organization (WHO), HIV remains a major global health concern that has infected more than 40.1 million lives since the first time it was diagnosed in humans. As of 2022, there is no cure for the disease even though the condition has become manageable owing to exhaustive measures undertaken by international agencies and regional governments.

As per a research study published in Nature Medicine, mRNA vaccines offer hope for the treatment of HIV patients given the remarkable results shown by the technology in battling Covid-19 infection. With years, the research community has managed to handle the various challenges associated with the instability of the vaccines as well as unfavorable immunogenicity but with time, the future looks more promising.

The major growth restriction with the adoption of mRNA vaccines is the lack of infrastructure supporting the testing and trial of the medicines in many parts of the world. Currently, there are only a handful of pharmaceutical companies that are working toward building mRNA-influenced therapeutics because they have the necessary resources at their disposal. The entire process of research, trial, launch, and production is expensive and so is the final treatment.

The increasing efforts to find a cancer cure could provide growth opportunities while slow research advancement may act as a major challenge.

Segmental Overview

The global messenger RNA (mRNA)-based vaccines and therapeutics market is segmented based on application, end-user, type, route of administration, and region

Based on end-user, the global market segments are clinics, hospitals, diagnostic centers, and others. In 2021, the global market registered the highest growth in the hospital segment due to the high number of people who were administered vaccines for Covid-19. mRNA therapeutics and drugs remained one of the final solutions for the development of effective vaccines against SARS-CoV-2.

Growth in the diagnostic center's segment was also related to the high influx of the population who got administered the vaccine. In 2021, Pfizer, one of the leading Covid-19 vaccine producers, generated a sales revenue of USD 26 billion. In the last quarter of 2020, Pfizer amassed USD 154 million.

Based on type, the global market divisions are infectious disease treatment mRNA Vaccine, infection prevention mRNA vaccine, standardization of cancer treatment mRNA vaccine, and individualized cancer treatment mRNA vaccine. By 2030, the global market players can expect a boost in the demand for individualized cancer treatment mRNA vaccines due to the increasing number of cancer patients. In the US, the number of patients reached 1.9 million in new cases.

Regional Overview

North America is projected to lead the global messenger RNA (mRNA)-based vaccines and therapeutics market due to higher demand for personalized vaccines supported by excellent healthcare. The US government has laid emphasis on increasing investment and research for mRNA-based drugs. To create mRNA vaccines, scientists must first correctly identify the protein that is present on the outside of the virus being studied.

The identified protein is what the body’s immunity system aims at. The protein chosen to be created with the help of the vaccine should be significantly different from the protein at the outer area of the virus so that the vaccine targets only the virus. Before the vaccines are made available in the commercial market for use, they have to undergo rigorous quality and safety checks since they can have a harmful impact or lead to serious conditions in case they are deemed unsafe. In December 2022, Moderna announced that it will build an mRNA vaccine manufacturing facility in the UK after receiving the government's approval.

Report Scope

Competitive Analysis:

The global messenger RNA (mRNA)-based vaccines and therapeutics market is led by players like Moderna Inc, Daiichi Sankyo Company, Limited, BioNTech, Pfizer, CureVac N.V., and others.

Recent Developments:

• In September 2021, Sanofi, a French multinational pharmaceutical company, announced an investment of 400 million euros annually to support research & development of next-generation vaccines using mRNA systems and technologies. The method proved highly effective for Moderna and Pfizer
• In April 2022, India-based Biological E announced that it will resource mRNA technology from WHO to initiate the production of Covid-19 vaccines in the country

The global Messenger RNA (mRNA) Vaccines & Therapeutics market is segmented as follows:

By Application

• Infectious Diseases
• Cancer
• Others

By End-User

• Clinics
• Hospitals
• Diagnostic Centers
• Others

By Type

• Infectious Disease Treatment mRNA Vaccine
• Infection Prevention mRNA Vaccine
• Standardization of Cancer Treatment mRNA Vaccine
• Individualized Cancer Treatment mRNA Vaccine

By Route Of Administration

• Subcutaneous
• IV Infusion

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com